基于比价分析法探讨抗肿瘤药物价格合理性

doi:10.19803/j.1672-8629.2021.12.14

中国药物警戒 ›› 2021, Vol. 18 ›› Issue (12): 1162-1165.
DOI: 10.19803/j.1672-8629.2021.12.14

基于比价分析法探讨抗肿瘤药物价格合理性

王江流¹, 刘平羽^1,*, 李歆², 韩峰²

¹南京医科大学第二附属医院,江苏南京 210011;
²南京医科大学药学院,江苏南京 211166

收稿日期:2021-03-07 出版日期:2021-12-15 发布日期:2021-12-16
通讯作者: ^*刘平羽,女,硕士,副主任药师,药物经济学、药物治疗学。E-mail：1018515698@qq.com
作者简介:王江流,男,主管药师,医院药学。
基金资助:
国家自然科学基金资助项目（72074123, 716731471）; 江苏省政策引导类计划（软科学研究）（BR2020043）

Rationality of Prices of Antineoplastic Drugs Based on Price Comparison Analysis

WANG Jingliu¹, LIU Pingyu^1,*, LI Xin², HAN Feng²

¹Department of Pharmacy, Second Affiliated Hospital of Nanjing Medical University, Nanjing Jiangsu 2100001;
²School of Pharmacy, Nanjing Medical University, Nanjing Jiangsu 210000, China

Received:2021-03-07 Online:2021-12-15 Published:2021-12-16

摘要/Abstract

摘要： 目的对比分析现行抗肿瘤药品价格,对其存在的不合理状况进行实证分析。方法提取2020年1月江苏省公布的262个集中采购及36个国家谈判抗肿瘤药物,利用比价分析法,对原研药及仿制药、各类抗肿瘤药物、一线抗肿瘤药物及靶向抗肿瘤药物价格进行对比分析。结果原研与仿制药品价格极差为32.28,价格差距较大;各类抗肿瘤药物的平均极差为194.70,均值为36.44,标准差为58.01;抗肿瘤治疗指南推荐的一线用药价格差距较大,紫杉醇极差为5.33,同样规格的国产药品极差为33.30~144.89元之间。结论目前我国各类抗肿瘤药物的价格差距较大,品种规格数量较多,仍需采取系列措施完善抗肿瘤药物价格的形成机制,建立抗肿瘤药物价格的平衡点,平衡医药产业发展与药物可及性之间的矛盾。

关键词: 比价分析, 抗肿瘤药, 药品价格, 合理性

Abstract: Objective To compare current prices of antineoplastic drugs and conduct an empirical analysis of irrationality.Methods Comparative analysis of prices was used to compare the prices of original drugs, generic drugs, antineoplastic drugs, first-line antineoplastic drugs and targeting agents. Results The price range between original and generic drugs was 32.28, which was significant difference. The average range, average value, and standard deviation of various antineoplastic drugs prices were 194.7, 36.44, and 58.01, respectively. The prices of first-line drugs recommended by the anti-tumor treatment guidelines varied widely. For example, the range of paclitaxel was 5.33, and the range of domestic drugs with the same specifications was between 33.3 and 144.89.Conclusion There is a large price range and a large variety of antineoplastic drugs with different specifications in China. A series of measures needs to be taken to improve the mechanism of pricing, strike a balance between prices of antineoplastic drugs, and solve the contradiction between the development of the pharmaceutical industry and drug accessibility.

Key words: price comparison analysis, antineoplastic drugs, drug prices, rationality

中图分类号:

R994.11R916.696

王江流, 刘平羽, 李歆, 韩峰. 基于比价分析法探讨抗肿瘤药物价格合理性[J]. 中国药物警戒, 2021, 18(12): 1162-1165.

WANG Jingliu, LIU Pingyu, LI Xin, HAN Feng. Rationality of Prices of Antineoplastic Drugs Based on Price Comparison Analysis[J]. Chinese Journal of Pharmacovigilance, 2021, 18(12): 1162-1165.

参考文献

[1] GBD 2016 Healthcare Access and Quality Collaborators. Measuring performance on the healthcare access and quality index for 195 countries and territories and selected subnational locations: a systematic analysis from the global burden of disease study 2016BD 2016 Healthcare Access and Quality Collaborators. Measuring performance on the healthcare access and quality index for 195 countries and territories and selected subnational locations: a systematic analysis from the global burden of disease study 2016[J]. Lancet, 2018, 391(10136): 2236-2271.
[2] Wang Y.Price Theory and Price Management(价格理论与价格管理)[M]. Beijing: China Price Press, 2000.
[3] Guo Y.The study of chinese drug price management model[D].Shenyang: Shenyang Pharmaceutical University, 2002.
[4] Xue W.SPSS Statistical Analysis Method and Application(SPSS统计分析方法及应用)[M]. Beijing: Electronic Industry Press, 2004.
[5] Lv LT, Yu LJ.Comparative study of Sino-British cancer drug policies[J]. Health Policy Research in China(中国卫生政策研究), 2019, 12(2): 16-19.
[6] Rong YN.Comparison and enlightenment of outpatient medicine compensation policies in some european countries[J]. Chinese Hospital Management(中国医院管理), 2019, 39(6): 77.
[7] Liu QF.The implications of the japanese drug price negotiation for China[J]. Chinese Journal of Pharmaceuticals(中国医药工业杂志), 2018, 49(10): 1477.
[8] National Health Commission.2020 China Health Statistics Yearbook(2020中国卫生健康统计年鉴)[M]. Beijing: Peking Union Medical College Press, 2020.
[9] Hu SL.Analysis on economics theoretical basis and impact in drug bulk purchasing with quantity[J]. Soft Science of Health(卫生软科学), 2019, 33(1): 4.
[10] WHO. Meeting Report on Fair Pricing Forum[R]. Amsterdam, The Netherlands, 2017.

[1]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[2]	熊玮仪, 任经天. 抗肿瘤药说明书安全性信息上市后修订的考虑要点[J]. 中国药物警戒, 2024, 21(1): 94-97.
[3]	李容容, 李盟, 苟悦, 罗琼, 吕桦, 孙鑫, 刘成海. 113例抗肿瘤药物相关肝损伤的临床特点及危险因素分析[J]. 中国药物警戒, 2023, 20(5): 505-510.
[4]	罗世书, 屈杰, 周楠, 徐翠香, 刘屹, 张丽洁, 王建华. 289例单克隆抗体抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2023, 20(4): 444-448.
[5]	杨岩, 周德喜, 吴欣俐, 薛淑雅, 丁海华, 张泉, 张云玲. 84例新型抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2023, 20(3): 334-338.
[6]	姚鑫, 葛秋格, 李亚敏, 王一帆, 李媛媛, 刘志强. 2018~2022年某院新型抗肿瘤药物消化系统不良反应分析[J]. 中国药物警戒, 2023, 20(11): 1273-1278.
[7]	邰新娟, 马洪凤, 李君, 马维兴, 闫亚卫. 400例抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2022, 19(5): 541-544.
[8]	曹兆流, 张玮, 乔洋, 马宇昊, 韩峰, 李歆. 国内外抗肿瘤药物经济学评价文献计量学研究[J]. 中国药物警戒, 2021, 18(8): 737-742.
[9]	何璇, 王晓, 戴惠珍, 李歆, 韩峰. 2018年~2020年南京地区新型抗肿瘤药物利用分析[J]. 中国药物警戒, 2021, 18(8): 725-730.
[10]	蒋慧群, 李歆, 韩峰. 国家医保谈判抗肿瘤药物在常州地区可获得性和可负担性研究[J]. 中国药物警戒, 2021, 18(11): 1075-1079.
[11]	徐银莹, 陆子红, 李琪, 陆牡丹, 姜孙旻. 质子泵抑制剂对口服靶向抗肿瘤药物吸收影响的研究进展[J]. 中国药物警戒, 2021, 18(11): 1091-1096.
[12]	吴红, 李歆, 韩峰. 某三级肿瘤专科医院单克隆抗体类新型抗肿瘤药临床使用合理性与安全性分析[J]. 中国药物警戒, 2021, 18(10): 960-964.
[13]	赵爽, 古瑞, 宋燕青, 王向峰, 苗秋丽. 某院静脉输注抗肿瘤药说明书使用事项标注情况分析[J]. 中国药物警戒, 2021, 18(10): 978-980.
[14]	白顺民, 范哲. 某院静脉药物调配中心抗肿瘤药物不合理用药分析[J]. 中国药物警戒, 2020, 17(4): 239-244.
[15]	赵爽, 宋燕青, 王相峰, 金芳, 苗秋丽. 抗肿瘤药品说明书中儿童用药信息分析[J]. 中国药物警戒, 2019, 16(9): 555-560.

基于比价分析法探讨抗肿瘤药物价格合理性

Rationality of Prices of Antineoplastic Drugs Based on Price Comparison Analysis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics